Aravive Inc. (NASDAQ:ARAV), a late clinical-stage oncology company developing innovative therapeutics to treat life-threatening diseases, today announced that it received a $6 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the initiation of the global Phase 3 platinum resistant ovarian cancer (PROC) clinical trial in China for the development of Aravive’s batiraxcept.
Benchmark Maintains Buy on Rigetti Computing, Lowers Price Target to $8
Benchmark analyst David Williams maintains Rigetti Computing (NASDAQ:RGTI) with a Buy and lowers the price target from $10 to $8.
